SPDR S&P Regional Banking ETF (KRE)
- Previous Close
55.99 - Open
55.79 - Bid 56.63 x 3200
- Ask 56.86 x 800
- Day's Range
55.10 - 57.14 - 52 Week Range
37.66 - 57.64 - Volume
20,248,533 - Avg. Volume
13,497,254 - Net Assets 2.61B
- NAV 56.00
- PE Ratio (TTM) 10.13
- Yield 3.21%
- YTD Daily Total Return 7.99%
- Beta (5Y Monthly) 0.94
- Expense Ratio (net) 0.35%
In seeking to track the performance of the S&P Regional Banks Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the regional banks segment of the S&P Total Market Index ("S&P TMI").
SPDR State Street Global Advisors
Fund Family
Financial
Fund Category
2.61B
Net Assets
2006-06-19
Inception Date
Performance Overview: KRE
View MoreTrailing returns as of 7/18/2024. Category is Financial.
People Also Watch
Holdings: KRE
View MoreTop 10 Holdings (22.55% of Total Assets)
Sector Weightings
Recent News: KRE
View More
Research Reports: KRE
View MoreMorningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, online commerce set for acceleration, consolidation; the market may be missing changes afoot at Veolia; an overview of the moat ratings for big biotech firms; and Kraft Heinz, Tyson Foods, and Nutrien.
Biogen: Lowering Our Moat Rating to Narrow Based on MS Sales Pressure and Leqembi Uncertainty
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
RatingPrice TargetNetflix Earnings: Fantastic Period Dampened by Likelihood of Growth Deceleration
Netflix’s relatively simple business model involves only one business, its streaming service. It has the biggest television entertainment subscriber base in both the United States and the collective international market, with almost 250 million subscribers globally. Netflix has exposure to nearly the entire global population outside of China. The firm has traditionally avoided live programming or sports content, instead focusing on on-demand access to episodic television, movies, and documentaries. The firm recently began introducing ad-supported subscription plans, giving the firm exposure to the advertising market in addition to the subscription fees that have historically accounted for nearly all its revenue.
RatingPrice TargetAirbnb Earnings: Solid Demand and Profitability Set to Continue in 2024; Shares a Touch Rich
Started in 2008, Airbnb is the world’s largest online alternative accommodation travel agency, also offering booking services for boutique hotels and experiences. Airbnb’s platform offered over 7 million active accommodation listings as of Sept. 30, 2023. Listings from the company’s over 4 million hosts are spread over almost every country in the world. In the fourth quarter of 2022, 47% of revenue was from the North American region. Transaction fees for online bookings account for all its revenue.
RatingPrice Target